Suzhou Ribo Life Science (HKG:6938) reported positive Phase 2a results for its investigational therapy vortosiran (RBD4059) in patients with chronic coronary artery disease.
The study showed the small interfering RNA therapy was generally well tolerated and achieved dose-dependent, long-lasting suppression of coagulation factor XI activity in patients receiving aspirin therapy, with no treatment-related serious adverse events or major bleeding reported, according to a Hong Kong bourse filing on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments